Thrombolytic Therapy and Inflammatory Markers in Acute Pulmonary Embolism
Author Information
Author(s): Muacevic Alexander, Adler John R, Kaleli Muhammed Fatih, Sahin Ahmet T, Alsancak Yakup
Primary Institution: Necmettin Erbakan University
Hypothesis
This study aimed to evaluate the effects of thrombolytic therapy on inflammatory markers in patients diagnosed with acute pulmonary embolism.
Conclusion
The study found that inflammatory markers like SII, NLR, and MII-1 are elevated in acute pulmonary embolism and decrease after thrombolytic therapy, suggesting their potential use in monitoring treatment effectiveness.
Supporting Evidence
- Levels of CRP, WBC, SII, NLR, and MII-1 were significantly increased in the pulmonary embolism group compared to the control group.
- Post-thrombolytic treatment levels of CRP, WBC, neutrophils, lymphocytes, hemoglobin, SII, NLR, and MII-1 were significantly lower compared to pre-thrombolytic treatment levels.
- The study suggests that SII, NLR, and MII-1 could be useful for monitoring treatment effectiveness.
Takeaway
This study looked at how a treatment for blood clots affects certain markers in the body that show inflammation, finding that the treatment helps lower these markers.
Methodology
The study was conducted retrospectively on 138 individuals, comparing inflammatory markers before and after thrombolytic therapy.
Potential Biases
The study may have bias risks due to its retrospective design and the exclusion of certain patient data.
Limitations
The study's limitations include its single-center design, retrospective nature, and a relatively small sample size.
Participant Demographics
56.5% female, 43.5% male; 72.5% had diabetes, 61.5% had hypertension, 84.7% had chronic kidney disease.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website